How to analyze biotech clinical trials / A chat with Frank S. David, MD, PhD

00:07 Introduction to Frank S. David, MD, PhD 01:56 Challenges assessing biotech clinical trials 07:07 Some of the reasons for the recent biotech sector performance 16:50 A clinical trial data analysis example: Calliditas Therapeutics, Tarpeyo's IgA Nephropathy data 40:33 About the new book "Analyzing biotech clinical trials" Our biotech analyst Dan Akschuti had a chat with Frank S. David, MD, PhD, the founder and managing partner of Pharmagellan on his new, one-of-its-kind book “Analyzing biotech clinical trials”. We consider the book as a unique educational piece that manages to connect the many dots required to holistically understand clinical trials and their implications from a corporate strategy point of view. We believe that decision makers within biotech as well as for fund managers active within the space, both generalists and specialists will benefit the most from the “connected insights” of this book.